BS Reads: Lessons for India Inc from cricket win and slow vaccine embrace

While Team India's can-do attitude in the face of imminent loss got them top honours, Serum and Bharat Biotech failed to gauge the impact of exogenous factors on two high-potential health products

India’s dramatic cricket victory at the Gabba, Australia, and her underwhelming Covid-19 vaccine adoption in the country are classic cases of how risk was managed differently in two instances. One offered a positive outcome and the other a not-so-optimistic one.

The first demonstrated how a young, freshly-minted team raring to go could overcome the risks of possible failure with a can-do attitude and the latter showed how two Indian vaccine makers who bet big on a high market potential healthcare product were caught off-guard by controversies and exogenous events, especially from the media and the government.

What then are the